MA42444A - Traitement du prurit - Google Patents

Traitement du prurit

Info

Publication number
MA42444A
MA42444A MA042444A MA42444A MA42444A MA 42444 A MA42444 A MA 42444A MA 042444 A MA042444 A MA 042444A MA 42444 A MA42444 A MA 42444A MA 42444 A MA42444 A MA 42444A
Authority
MA
Morocco
Prior art keywords
pruritus
treatment
Prior art date
Application number
MA042444A
Other languages
English (en)
Inventor
Matthew D Linnik
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA42444A publication Critical patent/MA42444A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA042444A 2015-07-16 2016-07-07 Traitement du prurit MA42444A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562193335P 2015-07-16 2015-07-16

Publications (1)

Publication Number Publication Date
MA42444A true MA42444A (fr) 2018-05-23

Family

ID=56464322

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042444A MA42444A (fr) 2015-07-16 2016-07-07 Traitement du prurit

Country Status (13)

Country Link
US (1) US20180201673A1 (fr)
EP (1) EP3322725A1 (fr)
JP (1) JP2018521047A (fr)
KR (1) KR20180017145A (fr)
CN (1) CN107849128A (fr)
AU (1) AU2016294332A1 (fr)
BR (1) BR112017025264A2 (fr)
CA (1) CA2988240A1 (fr)
EA (1) EA201792527A1 (fr)
IL (1) IL255498A (fr)
MA (1) MA42444A (fr)
MX (1) MX2018000694A (fr)
WO (1) WO2017011260A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111032691A (zh) * 2017-08-23 2020-04-17 伊莱利利公司 生殖器银屑病的治疗
US12110323B2 (en) 2018-05-17 2024-10-08 Jiangsu Qyuns Therapeutics Co., Ltd. Anti-human interleukin 17A monoclonal antibody and application thereof
CN120241997A (zh) * 2019-02-18 2025-07-04 伊莱利利公司 治疗性抗体制剂
CN115362173A (zh) * 2020-04-17 2022-11-18 伊莱利利公司 呼吸系统疾病的治疗
CN118078988A (zh) * 2024-04-19 2024-05-28 正大天晴药业集团南京顺欣制药有限公司 包含靶向il-17a的抗体药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846039B2 (en) 2002-04-26 2014-09-30 Asan Laboratories Company (Cayman), Limited Method for ameliorating pruritus
BRPI0510617A (pt) * 2004-05-03 2007-10-30 Schering Corp uso de expressão de il-17 para prever inflamação de pele; processos de tratamento
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1963368B3 (fr) 2005-12-13 2020-06-10 Eli Lilly And Company Anticorps anti-il-17
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CA2708065C (fr) 2007-12-05 2015-02-24 Chugai Seiyaku Kabushiki Kaisha Agent therapeutique contre le prurit
WO2012125680A1 (fr) * 2011-03-16 2012-09-20 Novartis Ag Méthodes de traitement de vascularite à l'aide d'un molécule de liaison à l'il-17
WO2014107737A2 (fr) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Administration locale d'inhibiteurs de l'il-17 en vue du traitement d'affections oculaires

Also Published As

Publication number Publication date
JP2018521047A (ja) 2018-08-02
US20180201673A1 (en) 2018-07-19
EA201792527A1 (ru) 2018-06-29
WO2017011260A1 (fr) 2017-01-19
KR20180017145A (ko) 2018-02-20
BR112017025264A2 (pt) 2018-08-07
CA2988240A1 (fr) 2017-01-19
IL255498A (en) 2018-01-31
MX2018000694A (es) 2018-05-07
CN107849128A (zh) 2018-03-27
EP3322725A1 (fr) 2018-05-23
AU2016294332A1 (en) 2017-11-30

Similar Documents

Publication Publication Date Title
EP3488001A4 (fr) Traitement du cancer
EP3288383A4 (fr) Méthodes de traitement du cancer
MA43190A (fr) Traitement de la dyslipidémie mixte
EP3261641A4 (fr) Traitement de la pancréatite
DK3851537T5 (da) Behandling af hyperbilirubinæmi
PL3212174T3 (pl) Sposoby leczenia zakażeń wirusem filoviridae
EP2968208A4 (fr) Traitement de la cataplexie
HUE057377T2 (hu) Kolesztatikus pruritus kezelése seladelparral
EP3432888A4 (fr) Traitement du cancer avec tg02
EP3376950A4 (fr) Représentation du soulagement de symptômes
DK3453721T3 (da) Process of manufacture of annexin v
EP3389634A4 (fr) Méthodes de traitement du cancer
EP3375108A4 (fr) Traitement dewlan
DK3132009T3 (da) Fremgangsmåde
EP3359255A4 (fr) Polythérapies pour le traitement du cancer
EP3307280A4 (fr) Traitement de dysfonction sexuelle
DK3283210T3 (da) Fremgangsmåde
PL3393468T3 (pl) Metody leczenia niedoboru odporności
LT3307267T (lt) Išsėtinės sklerozės gydymas
EP3334432A4 (fr) Cerdulatinib pour le traitement du myélome
EP3389652A4 (fr) Méthodes de traitement du cancer
IL257764B (en) Methods for treatment of diseases
IL254825A0 (en) Methods of treatment with taselisib
IL256111B1 (en) Pac–1 combination therapy
EP3328384A4 (fr) Traitement de la fibrose